152 related articles for article (PubMed ID: 21946231)
1. What controls PTEN and what it controls (in prostate cancer).
Ghosh PM
Asian J Androl; 2012 Jan; 14(1):130-1. PubMed ID: 21946231
[No Abstract] [Full Text] [Related]
2. Akt-regulated pathways in prostate cancer.
Majumder PK; Sellers WR
Oncogene; 2005 Nov; 24(50):7465-74. PubMed ID: 16288293
[TBL] [Abstract][Full Text] [Related]
3. [Signal transduction pathways involved in progression to androgen-independent prostate cancer].
Inoue T
Nihon Rinsho; 2011 Jun; 69 Suppl 5():121-5. PubMed ID: 22207955
[No Abstract] [Full Text] [Related]
4. [Dermatological implications of the PI3K pathway].
Dereure O
Ann Dermatol Venereol; 2015 Oct; 142(10):622-3. PubMed ID: 26001484
[No Abstract] [Full Text] [Related]
5. SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.
Blattner M; Liu D; Robinson BD; Huang D; Poliakov A; Gao D; Nataraj S; Deonarine LD; Augello MA; Sailer V; Ponnala L; Ittmann M; Chinnaiyan AM; Sboner A; Chen Y; Rubin MA; Barbieri CE
Cancer Cell; 2017 Mar; 31(3):436-451. PubMed ID: 28292441
[TBL] [Abstract][Full Text] [Related]
6. SOX4 Is Essential for Prostate Tumorigenesis Initiated by PTEN Ablation.
Bilir B; Osunkoya AO; Wiles WG; Sannigrahi S; Lefebvre V; Metzger D; Spyropoulos DD; Martin WD; Moreno CS
Cancer Res; 2016 Mar; 76(5):1112-21. PubMed ID: 26701805
[TBL] [Abstract][Full Text] [Related]
7. Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells.
Wu Z; Conaway M; Gioeli D; Weber MJ; Theodorescu D
Prostate; 2006 Jul; 66(10):1114-23. PubMed ID: 16637073
[TBL] [Abstract][Full Text] [Related]
8. Faithfull modeling of PTEN loss driven diseases in the mouse.
Nardella C; Carracedo A; Salmena L; Pandolfi PP
Curr Top Microbiol Immunol; 2010; 347():135-68. PubMed ID: 20549475
[TBL] [Abstract][Full Text] [Related]
9. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
10. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice.
Narayanan NK; Nargi D; Randolph C; Narayanan BA
Int J Cancer; 2009 Jul; 125(1):1-8. PubMed ID: 19326431
[TBL] [Abstract][Full Text] [Related]
11. Akt in prostate cancer: possible role in androgen-independence.
Ghosh PM; Malik S; Bedolla R; Kreisberg JI
Curr Drug Metab; 2003 Dec; 4(6):487-96. PubMed ID: 14683476
[TBL] [Abstract][Full Text] [Related]
12. Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.
McCubrey JA; Sokolosky ML; Lehmann BD; Taylor JR; Navolanic PM; Chappell WH; Abrams SL; Stadelman KM; Wong EW; Misaghian N; Horn S; Bäsecke J; Libra M; Stivala F; Ligresti G; Tafuri A; Milella M; Zarzycki M; Dzugaj A; Chiarini F; Evangelisti C; Martelli AM; Terrian DM; Franklin RA; Steelman LS
Adv Enzyme Regul; 2008; 48():113-35. PubMed ID: 18423407
[TBL] [Abstract][Full Text] [Related]
13. The relation between PI3K/AKT signalling pathway and cancer.
Noorolyai S; Shajari N; Baghbani E; Sadreddini S; Baradaran B
Gene; 2019 May; 698():120-128. PubMed ID: 30849534
[TBL] [Abstract][Full Text] [Related]
14. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
Blando J; Portis M; Benavides F; Alexander A; Mills G; Dave B; Conti CJ; Kim J; Walker CL
Am J Pathol; 2009 May; 174(5):1869-79. PubMed ID: 19395652
[TBL] [Abstract][Full Text] [Related]
15. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Tan M; Xu J; Siddiqui J; Feng F; Sun Y
Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
[TBL] [Abstract][Full Text] [Related]
16. Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics.
Italiano A; Chen CL; Thomas R; Breen M; Bonnet F; Sevenet N; Longy M; Maki RG; Coindre JM; Antonescu CR
Cancer; 2012 Dec; 118(23):5878-87. PubMed ID: 22648906
[TBL] [Abstract][Full Text] [Related]
17. Akt Signaling Pathway in Macrophage Activation and M1/M2 Polarization.
Vergadi E; Ieronymaki E; Lyroni K; Vaporidi K; Tsatsanis C
J Immunol; 2017 Feb; 198(3):1006-1014. PubMed ID: 28115590
[TBL] [Abstract][Full Text] [Related]
18. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL
Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in
Yan Y; An J; Yang Y; Wu D; Bai Y; Cao W; Ma L; Chen J; Yu Z; He Y; Jin X; Pan Y; Ma T; Wang S; Hou X; Weroha SJ; Karnes RJ; Zhang J; Westendorf JJ; Wang L; Chen Y; Xu W; Zhu R; Wang D; Huang H
EMBO Mol Med; 2018 Apr; 10(4):. PubMed ID: 29523594
[TBL] [Abstract][Full Text] [Related]
20. PI3K/PTEN/Akt and TSC/mTOR signaling pathways, ovarian dysfunction, and infertility: an update.
Makker A; Goel MM; Mahdi AA
J Mol Endocrinol; 2014 Dec; 53(3):R103-18. PubMed ID: 25312969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
